Google’s life sciences unit, Verily Life Sciences, is considering filing for regulatory approval from the U.S. Food and Drug Administration (FDA) for its glucose-sensing smart contact lens, according to a report by The Wall Street Journal.
If approved, the smart lens would be the first of its kind to continuously monitor glucose levels in tears, potentially revolutionizing diabetes management. Currently, people with diabetes must prick their fingers multiple times a day to check their blood sugar levels.
The smart lens, which has been in development for over a decade, uses a miniaturized sensor and wireless transmitter to send glucose readings to a companion app on a smartphone or other device. The app can then provide real-time data and alerts, helping users manage their diabetes more effectively.
Verily has reportedly been conducting clinical trials of the smart lens for several years and has collected data from hundreds of participants. The company is now said to be analyzing the data and preparing to submit an application to the FDA for approval.
The FDA approval process for medical devices can be lengthy and rigorous, and it is unclear when the smart lens might receive clearance. However, if approved, it would be a significant advancement in diabetes care and could improve the lives of millions of people worldwide.
In addition to the smart lens, Verily is also developing other medical devices and technologies, including a smartwatch that can detect early signs of Parkinson’s disease and a pill that can deliver drugs directly to the stomach. The company’s mission is to improve healthcare through technology and data, and its work has the potential to make a major impact on public health.
The development of the glucose-sensing smart lens is a testament to the power of technology to address unmet medical needs. If successful, the lens could make diabetes management easier and more convenient, potentially leading to better health outcomes for people with the condition..
